SHAREme.

Scientific Hub of Applied Research in Emerging Medical science & technology

Received: 17.08.2024 Revised: 30.08.2024 Accepted: 02.09.2024

check for updates

Review Article

Brain-Eating Amoeba: A Comprehensive Review of Naegleria fowleri Infections and Primary Amoebic Meningoencephalitis

N Sriram [1] Aithamraju Satish Chandra [*2]

[1] *Department of Pharmacy, Florance college of Pharmacy, Ranchi, Jharkhand, India*

[2] *Department of Pharmacy practice, KVK college of Pharmacy, Hayathnagar, Telangana, India*

Primary amoebic meningoencephalitis (PAM) is a rare but highly fatal infection of the central nervous system caused by the free-living amoeba, Naegleria fowleri. Known colloquially as the brain-eating amoeba, N. fowleri is predominantly found in warm freshwater environments, such as lakes, rivers, and poorly maintained swimming pools. Infection typically occurs when contaminated water enters the nasal passages, allowing the amoeba to travel to the brain via the olfactory nerve. Primary amoebic meningoencephalitis progresses rapidly, with symptoms ranging from headache and fever to seizures and coma, often resulting in death within a week of symptom onset. This review provides a comprehensive overview of N. fowleri, including its biology, epidemiology, pathogenesis, clinical presentation, diagnostic challenges, current treatment strategies, and public health measures for prevention. We also explore emerging research and future directions for developing more effective diagnostic and therapeutic approaches. Understanding the complex interaction between N. fowleri and its human host is crucial for improving outcomes and developing effective prevention strategies. This review aims to enhance awareness and understanding among healthcare providers and public health professionals to better manage and prevent this devastating infection.

Keywords: Brain-eating amoeba, Naegleria fowleri, primary amoebic meningoencephalitis, Primary amoebic meningoencephalitis, free-living amoeba.

1. Introduction

Naegleria fowleri, also known as the "brain-eating amoeba," is a free-living amoeba that thrives in warm freshwater environments, such as lakes, rivers, hot springs, and inadequately chlorinated swimming pools. Although infections are rare, N. fowleri is the causative agent of primary amoebic meningoencephalitis (PAM), a rapidly progressing and often fatal disease of the central nervous system.

Primary amoebic meningoencephalitis typically occurs when water containing N. fowleri enters the nasal passages, allowing the amoeba to migrate along the olfactory nerve to the brain, where it induces a severe inflammatory response and extensive tissue necrosis [1]. Despite its rarity, the high mortality rate associated with Primary amoebic meningoencephalitis, often exceeding 97%, makes it a significant public health concern, particularly in regions with warm climates where the amoeba is more prevalent [2]. This review aims to provide a comprehensive overview of the current understanding of N. fowleri infections, including their biology, epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and

Correspondence should be addressed to
Dr. Aithamraju Satish Chandra;
satishchandrano.1@gmail.com

prevention strategies. Through this synthesis, we aim to enhance the knowledge base of healthcare providers and public health officials, promoting early diagnosis and intervention to improve patient outcomes.

2. Biology and Epidemiology of N. fowleri

2.1. Taxonomy and Morphology

Naegleria fowleri belongs to the phylum Percolozoa and is classified within the family Vahlkampfiidae. It is a thermophilic organism that thrives in warm freshwater environments, where it exists in three distinct morphological forms: trophozoite, flagellate, and cyst. The trophozoite stage is the only form that is pathogenic to humans and is responsible for causing Primary amoebic meningoencephalitis. Trophozoites are amoeboid in shape, measuring approximately 10 to 35 micrometers, and exhibit characteristic lobose pseudopodia, which aid in locomotion and phagocytosis [3]. Under unfavorable conditions, such as nutrient deprivation or exposure to cold temperatures, the trophozoites can transform into a flagellate form, which possesses two flagella and is capable of rapid movement. This form is typically temporary and reverts back to the trophozoite form when conditions improve. In harsh environmental conditions, N. fowleri can encyst, forming a spherical, double-walled cyst that is resistant to desiccation, temperature extremes, and disinfection [1]. Understanding the biology and morphological adaptations of N. fowleri is crucial for developing effective diagnostic and therapeutic strategies, as each form exhibits different susceptibilities to environmental conditions and chemical agents.

2.2. Distribution and Epidemiology

Naegleria fowleri is found worldwide, with reported cases in North America, Europe, Asia, Australia, and Africa, although the majority of documented cases have occurred in the United States, particularly in the southern states where warm freshwater bodies are more common [3]. The amoeba is typically found in warm freshwater environments, such as lakes, rivers, hot springs, and poorly maintained swimming pools, especially during the summer months when water temperatures are higher. The incidence of PAM is closely associated with environmental factors, including water temperature, pH, and the presence of organic matter, which provides a nutrient source for the amoeba [4]. Recent epidemiological studies have indicated that climate change, leading to warmer global temperatures and increased use of recreational freshwater activities, may contribute to the geographic expansion of N. fowleri and the rise in reported cases of Primary amoebic meningoencephalitis [3]. Surveillance and monitoring of environmental water sources, coupled with public health education on the risks of exposure, are essential strategies for preventing N. fowleri infections.

3. Pathogenesis of N. fowleri Infection

3.1. Mechanism of Infection

The pathogenesis of Naegleria fowleri infection begins when the trophozoites enter the human host through the nasal cavity, typically during activities such as swimming, diving, or submerging in contaminated water. Upon entry, the trophozoites attach to the olfactory epithelium, where they migrate along the olfactory nerve fibers, penetrating the cribriform plate to reach the brain [5]. The migration of N. fowleri to the brain is facilitated by its production of various proteolytic enzymes, including phospholipases, cysteine proteases, and serine proteases, which degrade the extracellular matrix and disrupt cellular junctions, allowing the amoeba to traverse neural tissues [6]. Once in the brain, the trophozoites induce a robust inflammatory response, characterized by the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). This inflammatory response, although initially aimed at controlling the infection, leads to significant tissue damage, edema, and necrosis, exacerbating the disease progression [7]. The rapid multiplication of trophozoites within the brain parenchyma, coupled with their ability to evade the host immune response, results in a fulminant and often fatal disease course.

3.2. Immune Response and Host Interaction

The host immune response to N. fowleri infection involves both innate and adaptive immune mechanisms. Upon entry into the nasal cavity and subsequent migration to the brain, the amoeba triggers an intense inflammatory response mediated by neutrophils, macrophages, and microglia [6]. These immune cells release reactive oxygen species (ROS) and pro-inflammatory cytokines in an attempt to

eliminate the amoeba. However, N. fowleri has evolved several strategies to evade host defenses, including the secretion of antioxidant enzymes that neutralize ROS, modulation of host cell apoptosis to avoid immune detection, and the production of molecules that inhibit complement activation [7]. These mechanisms allow N. fowleri to survive and proliferate within the brain, leading to extensive neuronal damage and, ultimately, death. The complex interplay between N. fowleri and the host immune system is a critical area of research, as it provides insights into potential therapeutic targets for enhancing host defenses and developing novel treatments for Primary amoebic meningoencephalitis.

4. Clinical Manifestations and Diagnosis of Primary Amoebic Meningoencephalitis (PAM)

4.1. Clinical Presentation

Primary amoebic meningoencephalitis (PAM) presents with a rapid onset of non-specific symptoms, which often leads to delays in diagnosis and treatment. The initial symptoms of Primary amoebic meningoencephalitis typically appear within 2 to 15 days post-exposure and include fever, headache, nausea, vomiting, and stiff neck—symptoms that are commonly mistaken for bacterial or viral meningitis [8]. As the infection progresses, patients may develop altered mental status, seizures, hallucinations, and focal neurological deficits. The rapid progression of these symptoms reflects the aggressive nature of the amoebic infection and the extensive damage to brain tissue caused by both the direct cytopathic effects of the amoeba and the inflammatory response [8]. The disease often culminates in coma and death within a week of symptom onset, underscoring the need for prompt diagnosis and intervention. The high mortality rate associated with Primary amoebic meningoencephalitis , often exceeding 97%, is largely due to the difficulty in distinguishing it from other forms of meningitis based on clinical presentation alone, highlighting the need for increased awareness and improved diagnostic methods [2].

4.2. Diagnostic Techniques

Diagnosing Primary amoebic meningoencephalitis is challenging due to its rare occurrence and non-specific clinical presentation. Traditional diagnostic methods include microscopic examination of cerebrospinal fluid (CSF) for the presence of motile trophozoites, which can be observed using wet mount preparations [9]. However, this method requires immediate sample processing and expertise in identifying the amoeba, which is not always feasible in clinical settings. More advanced diagnostic techniques, such as polymerase chain reaction (PCR) and real-time PCR, have been developed to detect N. fowleri DNA in CSF samples with high sensitivity and specificity, providing a more reliable diagnostic approach [10]. Immunohistochemical staining and indirect immunofluorescence assays can also aid in diagnosis, particularly in cases where amoebae are not readily detectable by microscopy. Imaging modalities, including computed tomography (CT) and magnetic resonance imaging (MRI), may reveal brain edema and hemorrhagic necrosis, but these findings are non-specific and cannot definitively distinguish Primary amoebic meningoencephalitis from other causes of meningoencephalitis [4]. Given the rapid progression of Primary amoebic meningoencephalitis , early and accurate diagnosis is crucial for initiating appropriate therapy and improving patient survival rates.

5. Treatment Strategies for N. fowleri Infection

5.1. Antimicrobial Therapy

The treatment of Primary amoebic meningoencephalitis requires a combination of antimicrobial therapy and supportive care. Amphotericin B, an antifungal agent, remains the cornerstone of treatment due to its amoebicidal activity against N. fowleri. It can be administered intravenously and intrathecally to target the infection directly within the central nervous system [11]. Miltefosine, an anti-leishmanial drug, has shown promise as an adjunctive therapy due to its ability to penetrate the blood-brain barrier and its efficacy against free-living amoebae [2]. Other drugs, such as rifampin, fluconazole, and azithromycin, are often used in combination with amphotericin B and miltefosine to provide broad-spectrum coverage and enhance treatment efficacy [4]. Despite these options, the overall survival rate for Primary amoebic meningoencephalitis remains low, emphasizing the need for early diagnosis and aggressive treatment.

Emerging therapies, including immune modulators and targeted molecular therapies, are currently under investigation to improve patient outcomes [7].

5.2. Supportive and Adjunctive Therapies

Supportive care is essential in managing patients with Primary amoebic meningoencephalitis, as the disease often leads to severe neurological deficits and multi-organ dysfunction. Management strategies include controlling intracranial pressure, maintaining adequate oxygenation and ventilation, and providing hemodynamic support [7]. Corticosteroids may be used to reduce cerebral edema, although their effectiveness in improving outcomes remains controversial. Experimental adjunctive therapies, such as therapeutic hypothermia and the use of neuroprotective agents, have shown potential in animal models but require further investigation in clinical settings [7]. Given the high mortality rate associated with Primary amoebic meningoencephalitis, exploring novel therapeutic approaches that could enhance the efficacy of current treatments and provide new avenues for intervention is crucial. Continued research into the pathophysiology of N. fowleri infection and host response mechanisms will be vital for developing more effective therapeutic strategies.

6. Prevention and Public Health Measures

6.1. Risk Factors and Environmental Controls

Preventing N. fowleri infections requires a comprehensive understanding of the environmental factors that contribute to its proliferation and transmission. Key risk factors include recreational water use in warm, freshwater environments, particularly during the summer months when water temperatures are elevated [3]. Public health measures should focus on educating the public about the risks associated with warm freshwater activities and promoting safe water practices, such as avoiding nasal exposure to contaminated water [12]. Environmental controls, including proper maintenance and chlorination of swimming pools and hot tubs, are also critical in reducing the risk of N. fowleri proliferation. In areas where N. fowleri is known to be present, regular monitoring of water sources and implementation of water treatment protocols can help mitigate the risk of exposure [13].

6.2. Public Awareness and Education

Raising public awareness about N. fowleri and Primary amoebic meningoencephalitis is essential for preventing infections and promoting early diagnosis and treatment. Public health campaigns should focus on educating individuals about the risks associated with recreational water activities and the importance of seeking prompt medical attention if symptoms develop after exposure to warm freshwater [13]. Guidelines for safe water practices, such as using nose clips while swimming or avoiding diving into warm freshwater, should be widely disseminated through various media channels [2]. Educational efforts should also target healthcare professionals to improve their understanding of Primary amoebic meningoencephalitis , its clinical presentation, and the appropriate diagnostic and therapeutic approaches [4]. Collaborative efforts between public health agencies, healthcare providers, and communities are vital to enhance awareness, reduce the incidence of N. fowleri infections, and improve patient outcomes.

7. Future Directions and Research Priorities

7.1. Advances in Research and Emerging Therapies

Recent advances in molecular biology and genomics have opened new avenues for understanding the pathogenesis of N. fowleri and developing targeted therapies. Research efforts are focused on identifying virulence factors and understanding the molecular mechanisms that enable N. fowleri to invade the brain and evade host immune responses [3]. Novel therapeutic strategies, including the use of targeted antibodies, small molecule inhibitors, and gene therapy, are being explored to enhance treatment efficacy. Additionally, the development of rapid diagnostic tools, such as point-of-care tests and next-generation sequencing techniques, holds promise for improving early diagnosis and treatment outcomes [11]. Future research should also focus on vaccine development and other preventive strategies to reduce the burden of N. fowleri infections globally [14].

7.2. Challenges and Knowledge Gaps

Despite recent advances, several challenges and knowledge gaps remain in the understanding and

management of N. fowleri infections. The rarity of Primary amoebic meningoencephalitis and the lack of awareness among healthcare providers contribute to delayed diagnosis and treatment, underscoring the need for continued education and training [2]. Furthermore, the development of effective treatments is hindered by the limited understanding of N. fowleri's molecular biology and host-pathogen interactions. Additional research is needed to elucidate the factors that contribute to the high mortality rate associated with Primary amoebic meningoencephalitis and to identify potential therapeutic targets [3]. Collaborative research efforts and increased funding are essential to advance our knowledge of N. fowleri and improve patient outcomes.

8. Conclusion

Primary amoebic meningoencephalitis caused by Naegleria fowleri is a rare but deadly infection with a high mortality rate. This review highlights the current understanding of the biology, epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of N. fowleri infections. Early diagnosis and aggressive treatment are crucial for improving patient outcomes, but the rarity of the disease and lack of specific clinical markers pose significant challenges. Continued research into the pathophysiology of N. fowleri and the development of novel diagnostic tools and therapies are essential for reducing the burden of this devastating infection. Public health efforts should focus on raising awareness about the risks associated with recreational water activities and promoting safe water practices to prevent future cases. Through a combination of research, education, and public health initiatives, we can improve outcomes for patients affected by this deadly pathogen and prevent future infections.

REFERENCE

[1] Schuster, F.L., & Visvesvara, G.S. (2004). Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. International Journal of Parasitology, 34(9), 1001-1027.

[2] Cope, J.R., & Ali, I.K.M. (2016). Primary amoebic meningoencephalitis: What have we learned in the last 50 years? Current Infectious Disease Reports, 18(10), 31.

[3] Maciver, S.K., Piñero, J.E., & Lorenzo-Morales, J. (2020). Is Naegleria fowleri an emerging parasite? Trends in Parasitology, 36(1), 19-28.

[4] Visvesvara, G.S., Moura, H., & Schuster, F.L. (2007). Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunology & Medical Microbiology, 50(1), 1-26.

[5] Grace, E., Asbill, S., & Virga, K. (2015). Naegleria fowleri: Pathogenesis, diagnosis, and treatment options. Antimicrobial Agents and Chemotherapy, 59(11), 6677-6681.

[6] Siddiqui, R., & Khan, N.A. (2016). Biology and pathogenesis of Naegleria fowleri. Acta Tropica, 164, 375-394.

[7] Kim, J.-H., Sohn, H.-J., Yoo, J.-K., Kang, H., Seong, G.-S., Chwae, Y.-J., Kim, K., Park, S., & Shin, H.-J. (2016). NLRP3 inflammasome activation in THP-1 target cells triggered by pathogenic Naegleria fowleri. Infection and Immunity, 84(8), 2422-2428.

[8] Ong, T.Y.Y., Khan, N.A., & Siddiqui, R. (2017). Brain-eating amoebae: Predilection sites in the brain and disease outcome. Journal of Clinical Microbiology, 55(6), 1989-1997.

[9] Martinez, A.J., & Visvesvara, G.S. (1997). Free-living, amphizoic, and opportunistic amebas. Brain Pathology, 7(5), 583-598.

[10] Singh, P., Kochhar, R., Vashishta, R.K., Khandelwal, N., Prabhakar, S., Mohindra, S., & Singhi, P. (2006). Amebic meningoencephalitis: Spectrum of imaging findings. American Journal of Neuroradiology, 27(6), 1217-1221.

[11] Pugh, J.J., & Levy, R.A. (2016). Naegleria fowleri: Diagnosis, pathophysiology of brain inflammation, and antimicrobial treatments. ACS Chemical Neuroscience, 7(9), 1178-1179.

[12] Matanock, A., Mehal, J.M., Liu, L., Blau, D.M., & Cope, J.R. (2018). Estimation of undiagnosed Naegleria fowleri primary amebic meningoencephalitis, United States. Emerging Infectious Diseases, 24(1), 162-164.

[13] Centers for Disease Control and Prevention (CDC). (2022). Naegleria fowleri—Primary Amebic

Meningoencephalitis (PAM)—Amebic Encephalitis. Available at: https://www.cdc.gov/parasites/naegleria/diagnosis. html

[14] Heggie, T.W. (2010). Swimming with death: Naegleria fowleri infections in recreational waters. Travel Medicine and Infectious Disease, 8(4), 201-206.